Sandwich assay for small molecules
AssigneeSiemens Healthcare Diagnostics Inc.
InventorTie Wei
Life of this patent
Estimating the term…
Abstract
Methods are disclosed for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,500. The method comprises the use of a first antibody that binds to the small molecule and a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a hapten that is not the small molecule or a derivative of the small molecule wherein the hapten comprises a moiety that is structurally similar to that of the second portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.
Claims20
A method of designing antibodies for a sandwich assay for an immunosuppressant drug having a molecular weight of about 500 to about 2,500, the method comprising the steps of:
- preparing a first monoclonal antibody that binds to and is specific for a first portion of the immunosuppressant drug by immunizing an antibody-producing animal with an immunogen that comprises the first portion of the immunosuppressant drug;
- and
- preparing a second monoclonal antibody that binds to the immunosuppressant drug at a second portion of the immunosuppressant drug other than the first portion to which the first monoclonal antibody binds, wherein the second monoclonal antibody is prepared by immunizing an antibody-producing animal with an immunogen that comprises a hapten that is not the immunosuppressant drug, wherein the hapten comprises a moiety that is structurally similar to that of the second portion of the immunosuppressant drug, and wherein the second monoclonal antibody is prepared and selected for the binding of both the hapten and the second portion of the immunosuppressant drug;
- and
- wherein the first and second monoclonal antibodies can bind simultaneously to the first and second portions of the immunosuppressant drug without interfering with the binding of each other to form a three-member complex.
A method of designing antibodies for a sandwich assay for an immunosuppressant drug having a molecular weight of about 500 to about 2,500, wherein the immunosuppressant drug is sirolimus or everolimus, the method comprising the steps of:
- preparing a first monoclonal antibody that binds to and is specific for a first portion of the immunosuppressant drug by immunizing an antibody-producing animal with an immunogen that comprises the first portion of the immunosuppressant drug;
- and
- preparing a second monoclonal antibody that binds to the immunosuppressant drug at a second portion of the immunosuppressant drug other than the first portion to which the first monoclonal antibody binds, wherein the second monoclonal antibody is prepared by immunizing an antibody-producing animal with an immunogen that comprises tacrolimus or a derivative of tacrolimus, and wherein the second monoclonal antibody is prepared and selected for the binding of both tacrolimus and the second portion of the immunosuppressant drug;
- and
- wherein the first and second monoclonal antibodies can bind simultaneously to the first and second portions of the immunosuppressant drug without interfering with the binding of each other to form a three-member complex.
A method of designing antibodies for a sandwich assay for tacrolimus, the method comprising the steps of:
- preparing a first monoclonal antibody that binds to and is specific for a first portion of tacrolimus by immunizing an antibody-producing animal with an immunogen that comprises the first portion of tacrolimus;
- and
- preparing a second monoclonal antibody that binds to a second portion of tacrolimus other than the first portion to which the first monoclonal antibody binds, wherein the second monoclonal antibody is prepared by immunizing an antibody-producing animal with an immunogen that comprises sirolimus or a derivative of sirolimus, and wherein the second monoclonal antibody is prepared and selected for the binding of both tacrolimus and sirolimus;
- and
- wherein the first and second monoclonal antibodies can bind simultaneously to the first and second portions of tacrolimus without interfering with the binding of each other to form a three-member complex.
Dependencies are inferred from the claim text.